×
About 15,890 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  4,707 results

ROR1 - An Orphan Becomes Apparent.
https://doi.org/10.1182/blood.2021014760
Blood Kipps TJ

May 18th, 2022 - Since its initial identification in 1992 as a possible class I cell-surface receptor without a known parent ligand, receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) has stimulated research, which has made apparent its significance in embryon...

SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases o...
https://doi.org/10.1016/j.clml.2022.04.017
Clinical Lymphoma, Myeloma & Leukemia; Burke JM

May 17th, 2022 - The introduction of targeted therapies in chronic lymphocytic leukemia (CLL) has ushered in a new era in which patients achieve better control of their disease, survive longer, and experience fewer toxicities than before. Despite this progress, a ...

TP53-altered CLL Treated with Firstline Bruton's Tyrosine Kinase Inhibitor-based Therap...
https://doi.org/10.1002/ajh.26595
American Journal of Hematology; Cherng HJ, Khwaja R et. al.

May 15th, 2022 - Long-term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53-altered chronic lymphocytic leukemia (CLL); however, it i...

The gut microbiome in patients with chronic lymphocytic leukemia.
https://doi.org/10.3324/haematol.2021.280455
Haematologica Faitová T, Svanberg R et. al.

May 14th, 2022 - Not available.

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
https://clinicaltrials.gov/ct2/show/NCT01139476

May 13th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

see more →

Guidelines  8 results

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940638
Leukemia Malcikova J, Tausch E et. al.

Feb 23rd, 2018 - In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Vers...
https://doi.org/10.6004/jnccn.2017.0030
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Zelenetz AD et. al.

Mar 10th, 2017 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmu...

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841457
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Mar 5th, 2015 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the develop...

Non-Hodgkin's lymphomas, version 1.2013.
https://doi.org/10.6004/jnccn.2013.0037
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Wierda WG et. al.

Mar 15th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recomme...

see more →

Drugs  46 results see all →

Clinicaltrials.gov  301 results

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 13th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT03986034

May 13th, 2022 - This study aims to study the clonal dynamics and kinetics of response during the ramp-up phase of venetoclax in chronic lymphocytic leukemia (CLL). Key Eligibility Criteria: Diagnosis of CLL/SLL (treatment naive or relapsed/refractory) Must have d...

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03479268

May 13th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIV...

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study
https://clinicaltrials.gov/ct2/show/NCT01139476

May 13th, 2022 - We propose to conduct a molecular epidemiology study with a subset of participants in the Agricultural Health Study (AHS), a prospective cohort of 57,310 licensed pesticide applicators in Iowa and North Carolina. Blood and urine samples will be co...

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT04895436

May 12th, 2022 - Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess how well venetoclax + obinutuzumab (VenG) works and how safe they are in adult participants with CLL who were previously...

see more →

News  1,285 results

Studies Address Ibrutinib Bleeding Risk in Patients With CLL Receiving Mohs Surgery
https://www.medscape.com/viewarticle/974234

May 18th, 2022 - Patients receiving treatment with ibrutinib for chronic lymphocytic leukemia (CLL) show significant increases in the risk for bleeding when undergoing Mohs micrographic surgery for skin cancer, indicating the need for temporary treatment interrupt...

'Agony of Choice' for Clinicians Treating Leukemia
https://www.medscape.com/viewarticle/973800

May 11th, 2022 - With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia (CLL), picking the optimal drug or drug sequence for the right situation can be a challenge, but emerging data is helping guide clinician...

‘Agony of choice’ for clinicians treating leukemia
https://www.mdedge.com/hematology-oncology/article/254465/cll/agony-choice-clinicians-treating-leukemia
Nancy A. Melville

May 10th, 2022 - With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia (CLL), picking the optimal drug or drug sequence for the right situation can be a challenge, but emerging data is helping guide clinician.

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer
https://www.onclive.com/view/car-t-cell-therapy-may-represent-a-new-option-in-medullary-thyroid-cancer

May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...

see more →

Patient Education  9 results see all →